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Abstract 
Background: A common problem during pregnancy is anemia and to reduce its prevalence the WHO and 
national guidelines recommend a prescription of 30 to 60 mg of iron/day. The aim of this study was to 
evaluate the association of iron profile, hepcidin and oxidative stress in pregnant women prescribed with 
iron as a probable cause of metabolic disorders.
Method: In this cohort study two groups were followed: A) women with low-risk pregnancy (WLRP), B) 
women with high-risk pregnancy (WHRP): women with metabolic disorders (dyslipidemias, GDM and high 
blood pressure). Oxidative stress enzymes, iron profile and hepcidin were measured in the second and third 
trimesters.
Results: There were significant differences in hepcidin levels between WLRP and WHRP in 2nd (3.6 ± 4.2 
vs 4.69 ± 3.23 P=0.005) and 3rd trimester (3.65 ± 3.44 vs 6.84 ± 5.14 P=0.02). The serum iron concentration 
had a negative relationship with catalase (-0.599; P=0.04) and a positive relationship with glutathione 
peroxidase (0.729; P=0.007). 
Conclusion: The iron serum levels increase could induce oxidative damage in pregnancy. Increased hepcidin 
is a useful biomarker for determining iron availability in pregnancy and its association with antioxidant 
systems. 
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Introduction
Between 2% and 5% of pregnancies in women 
older than 30 are associated with metabolic disorders1 
and 40.1% are related to anemia-associated nutritional 
deficits, being 50% of these due to iron deficiency.2 
Therefore, the prophylactic prescription of iron 
supplements has become routine in the gestational 
period,3 recommending from 30 to 60 mg of iron/day as 
a prophylactic dose during pregnancy to avoid anemia.4
The Mexican Institute of Social Security (IMSS) 
defined in 1959 a standardized supplemental dose of 60 
mg of elemental iron, generally supplied as 200 mg of 
ferrous sulfate/day based on estimates of pregnancy iron 
requirements between 3.5 to 4 mg/day. Moreover, the 
Mexican government recommends the administration of 
iron and folic acid as prophylactic prescription.2
It is well-known that iron participates in the 
generation and propagation of reactive oxygen species 
(ROS) and lipid hydroperoxides, which play an 
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important role in the pathophysiology of diseases such as 
gestational diabetes mellitus (GDM) and preeclampsia.5 
It is recognized that, to guarantee an absorption 
of between 4 and 7 mg/day of iron, at least 20 mg/day 
of this element should be consumed in the diet (20% 
bioavailability), and adding 60 mg/day of supplemented 
iron, a pregnant woman would receive 80 mg/day of 
which 16 mg/day would be absorbed, which implies a 
dose 4 to 8 times higher than the minimum requirement 
amount, leading possibly to an iron overloading 
exposition in the gastrointestinal system. Hence, iron 
overload results in an increase in total body iron stores, a 
situation that could favor oxidative stress in any system 
and in the body in general. 
Hepcidin peptide plays an important role in iron 
homeostasis since it regulates both iron absorption in 
the duodenum and its recycling process from senescent 
erythrocytes.6 The aim of this work was to evaluate 
the correlations among serum iron levels, hepcidin and 




This cohort study, carried out at the “Mónica Pretelini 
Sáenz” Maternal Perinatal Hospital (HMPMPS), 
Health Institute of the State of Mexico (ISEM), Toluca, 
Mexico, included pregnant women divided into two 
groups: A) women with low-risk pregnancy (WLRP), 
B) women with high-risk pregnancy (WHRP): women 
with metabolic disorders (dyslipidemias, GDM and high 
blood pressure). 
Accepting an alpha risk of 0.05 and a beta risk of 0.2 
in a two-sided test, 22 subjects per group were necessary 
to recognize as statistically significant a difference 
greater than or equal to 3 units for hepcidin levels with a 
common standard deviation of 3.5. 
The protocol was reviewed and approved by the 
HMPMPS Ethics in Research Committee (number: 
2018-10-608) and the volunteers signed an informed 
consent letter. All the procedures were conducted in 
accordance with the Declaration of Helsinki (Fortaleza, 
Brazil) and the General Health Law of Mexico. 
Inclusion and exclusion criteria
The inclusion criteria were pregnant women between 
18 and 40 years old in the 2nd trimester of gestation 
prescribed with ferrous sulfate (60 mg/day), presence 
of metabolic alterations for the risk group pregnancy 
(previously diagnosed by the treating physician based on: 
hypertension: systolic blood pressure (SBP) ≥ 140 mmHg 
and/or diastolic blood pressure (DBP) ≥ 90 mmHg): 
GDM; glucose > 130 mg/dL; dyslipidemia: cholesterol 
> 200 mg/dL and triglycerides > 150 mg/dL) or women 
with Low-Risk for control group. Pregnant women with 
congenital heart defects, uterine abnormalities, chronic 
degenerative diseases, pregnancies with congenitally 
abnormal fetuses, pregnancies with assisted reproductive 
technologies, history of smoking, type 2 diabetes mellitus 
(T2DM) and infectious, inflammatory or autoimmune 
diseases were excluded. Volunteers who abandoned the 
study or who were lost to follow-up were discarded from 
the final analysis. 
Data Source
A questionnaire completed by all the patients 
gathered their health status and sociodemographic data 
including information of weight, height, blood pressure, 
blood chemistry (glucose, cholesterol and triglycerides) 
and blood biometry.
Blood samples were obtained in the 2nd (14-27 
weeks of gestation) and 3rd trimester (28-42 weeks 
of gestation). The antioxidant activity was evaluated 
through the enzymatic quantification of catalase 
(CAT), superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) using the methods of Radis et al.7 
Misra, et al.8 Paglia et al.9 respectively, as well as lipid 
peroxidation (LPOx) levels (Buege method).10 The iron 
profile included serum iron, total iron-binding capacity 
(TIBC), unsaturated iron-binding capacity (UIBC) and 
iron saturation (%S). Ferritin was also measured by 
chemiluminescence and hepcidin quantification was 
done by sandwich ELISA (LifeSpan BioSciences, Inc.)
Sociodemographic data was analyzed by descriptive 
statistics. The medians of the biomarkers under study 
were compared using the Mann Whitney U test and in 
order to analyze the correlation among biomarkers, a 
Spearman correlation was performed. The IBM STPSS 
Statistics 22 program was used, setting a P value ≤ 0.05 
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as statistically significant. 
Results
Of 106 patients who met the inclusion criteria in 
the 2nd. trimester of gestation, 42 were discarded, 20 
did not want to sign the informed consent and 22 had 
inconsistent information. 64 volunteer patients, 23 in 
the WLRP group (mean age 23.8 ± 4.5 years, range: 18-
31) and 41 in the WHRP group (27.0 ± 5.8 years, range: 
18 to 31) participated in the study. Table 1 shows the 
population characteristics. 
In relation to blood chemistry (Table 2), glucose 
levels were significantly higher by 7.93% in the WHRG 
group compared with the WLRP group only in the 
2nd trimester. Cholesterol values  in the WHRP group 
were significantly higher in the 2nd and 3rd trimester 
compared with those obtained in the WLRP group, by 
19.7% and 17.3%, respectively. 
The triglyceride values  in the 2nd and 3rd trimester 
of the WHRP group were 1.67 and 1.65 times higher 
than those of the WLRP group. In the WLRP group, 
26% exceeded the reference values  for cholesterol in 
the 2nd trimester and 47.8% in the 3rd trimester. The 
triglyceride levels of 26% of the WLRP group were 
higher than 200 mg/dL in the 2nd trimester and 73.9% in 
the 3rd trimester. The WHRP group exceeded the 73.2% 
reference value  for cholesterol in the 2nd trimester and 
78.0% in the 3rd trimester. Likewise, for triglyceride, 
these percentages were 87.8% and 97.46%.
The results of the oxidative stress biomarkers show 
that SOD activity increased significantly between the 
2nd and 3rd trimester in both groups (WLRP 26% and 
WHRP 21.9%); the increments for GPx in the same order 
were 23.7% and 23.2%. Finally, LPOx levels increased 
34% in the WLRP group, but only 8.5% in the WHRP 
group without being significant.
Regarding iron profile, there was no significant 
difference between the study groups, nor between the 
trimesters of pregnancy. Notwithstanding, a higher 
hepcidin concentration was obtained in the WHRP 
group compared with the WLRP group for both the 2nd 
and 3rd trimester (23.2 and 46.6%, respectively). TIBC 
in the 3rd trimester of the WLRP group and in the 2nd 
and 3rd trimester of the WHRP group were higher than 
the reference values  (240 to 450 µg/dL).
To analyze the results of the iron profile, the groups 
were formed as follows: WLRP (n = 11) and WHRP (n 
= 12) (since only these volunteers had all the determined 
parameters). A significant difference between the groups 
was observed only for iron saturation in the 3rd trimester 
(Table 3). 
Finally, Spearman’s correlation (Table 4) showed 
as main results that serum iron concentration had a 
significant negative relationship with CAT (-0.599; 
P=0.04) and positive with GPx (0.729; P=0.007). A 
positive correlation was obtained between SOD and 
LPOx (0.395; P=0.007), being lower for the WLRP 
group (0.481; P=0.24). It was also observed that at a 
lower hepcidin concentration, the SOD activity in the 
3rd trimester of the WLRP group was higher (-0.6; 
P=0.050), and in the WHRP group the behavior was the 
opposite in the 2nd trimester of pregnancy. Interestingly, 
when the hepcidin concentration increased, the SOD 
activity also increased (0.615; P=0.033). For GPx 
activity, the correlation was negative with hepcidin 
(-0.636; P=0.026). 
Table 1. Population characteristics
 Variable
 
WLRP (N = 23) Mean ± SD WHRP (N = 41) Mean ± SD
2nd trimester 3rd trimester 2nd trimester 3rd trimester
Age (years) 23.8 ± 4.5 - 27.0 ± 5.8 -
Height (m) 1.58 ± 0.07 - 1.57 ± 0.07 -
Weight (kg) 66.7 ± 11.1 70.3 ± 11.05 72.4 ± 14.8 75.2 ± 14.6
BMI (kg/m2) 26.4 ± 3.9 27.8 ± 3.7 29.2 ± 5.02 30.4 ± 4.94
Gestation (weeks) 22.8 ± 3.9 32.7 ± 2 23.2 ± 3.9 32.6 ± 2.1
Systolic Blood Pressure (mm Hg) 103.3 ± 8.4 106.9 ± 7.0 111.4 ± 13.5 111.9 ± 10.0
Diastolic Blood Pressure (mm Hg) 63.6 ± 8.2 63.9 ± 5.8 66.7 ± 9.6 69.5 ± 9.5
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Abbreviations: BMI: Body Mass Index, WLRP: Women with Low-Risk, WHRP: Women with High-Risk 
Pregnancy. 
Table 2. Means of the results of blood chemistry, oxidative stress and hepcidin (N = 64)
Variable
WLRP (N = 23) WHRP (N = 41) Mann Whitney U test
2nd trimester 3rd trimester 2nd trimester 3rd trimester * † ‡ §
Glucose (mg/
dL) 83.7 ± 10.8 87.1 ± 11.4 91 ± 15.9 89.2 ± 13.5 0.206 0.026 0.568 0.711
Cholesterol 
(mg/dL) 187.5 ± 19.67 206.1 ± 37.9 233.5 ± 51.6 249.1 ± 62.4 0.15 <0.001 0.297 0.002
Triglycerides 
(mg/dL) 144.5 ± 33.71 193.5 ± 57.8 242.8 ± 72.6 318.8 ± 98.9 0.002 <0.001 <0.001 <0.001
SOD (µmol/g 
Hb) 470.2 ± 293.63 635.7 ± 253.4 432.2 ± 264.6 553.3 ± 274.3 0.049 0.68 0.043 0.26
CAT (nmol/g 
Hb) 570.1 ± 265.53 580.2 ± 314.2 475.8 ± 262.9 549.4 ± 295.1 0.852 0.177 0.301 0.828
GPx (µmol/g 
Hb) 14.0 ± 6.2 18.4 ± 7.9 13.3 ± 6.6 17.3 ± 6.2 0.049 0.45 0.007 0.506
LPOx (nmol/g 




3.6 ± 4.2 3.6 ± 3.4 4.7 ± 3.2 6.8 ± 5.1 0.806 0.005 0.199 0.02
Abbreviations: CAT: catalase, GPx: glutathione peroxidase, LPOx: lipid peroxidation, SOD: superoxide 
dismutase, WLRP: Women with Low-Risk, WHRP: Women with High-Risk Pregnancy.
* WLRP 2nd trimester vs. WLRP 3rd trimester.
† WLRP 2nd trimester vs. WHRP 2nd trimester.
‡ WHRP 2nd trimester vs. WHRP 3rd trimester.
§ WLRP 3rd trimester vs. WHRP 3rd trimester. 
Table 3. Means of the results of iron profile and hepcidin (n = 23).
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Variable  
WLRP (N = 11) WHRP (N = 12) Mann Whitney U test 
2nd trimester 3rdtrimester 2nd trimester 3rd trimester * † ‡ §
Iron (µg/
dL)  78.53 ± 33.73 86.54 ± 32.38 64.43 ± 18.75 69.6 ± 19.76 0.438 0.487 0.514 0.316
TIBC (µg/
dL) 439.35 ± 80.58 437.15 ± 81.58 463.47 ± 98 460.23 ± 97.85 0.949 0.487 0.799 0.525
UIBC (µg/




16.9 ± 7.12 20.35 ± 6.81 14 ± 4.26 15.08 ± 5.33 0.217 0.169 0.478 0.016
Ferritin (ng/
mL) 15.98 ± 12.45 18.92 ± 14.97 9.62 ± 2.94 11.55 ± 3.4 0.519 0.413 0.198 0.288
Hepcidin 
(ng/mL) 2.61 ± 3.12 3.38 ± 3.72 4.64 ± 3.69 7.17 ± 6.43 0.519 0.104 0.478 0.118
Abbreviations: TIBC: total iron-binding capacity, UIBC: unsaturated iron-binding capacity, WLRP: Women 
with Low-Risk pregnancy, WHRP: Women with High-Risk Pregnancy. 
* WLRP 2nd trimester vs. WLRP 3rd trimester.
† WLRP 2nd trimester vs. WHRP 2nd trimester.
‡ WHRP 2nd trimester vs. WHRP 3rd trimester.
§ WLRP 3rd trimester vs. WHRP 3rd trimester. 
Table 4. Correlation of biomarkers of iron profile and hepcidin with blood chemistry and oxidative stress
Variables 
WLRP and 









r P value r P value r P value r P value r P value
Iron - TIBC         0.608 0.036
Iron - UIBC -0.325 0.028         
Iron - %S 0.815 <0.001 0.918 <0.001 0.9 <0.001 0.76 0.004 0.579 0.049
Iron - Ferritin   0.818 0.002 0.818 0.002     
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Iron - CAT       -0.599 0.04   
Iron - GPx       0.729 0.007   
%S - TIBC -0.407 0.005         
%S - UIBC -0.646 <0.001 -0.683 0.02 -0.691 0.019     
%S - Ferritin   0.782 0.004 0.745 0.008     
%S - Glucose     -0.627 0.039     
%S - Triglycerides       -0.643 0.024   
Ferritin - UIBC   -0.756 0.007 -0.645 0.032     
Ferritin - Cholesterol     -0.645 0.032     
Ferritin - Triglycerides   0.645 0.032       
Ferritin - CAT -0.332 0.024         
Ferritin - LPOx         -0.632 0.028
TIBC - UIBC 0.92 <0.001 0.902 <0.001 0.845 0.001 0.839 0.001 0.734 0.007
TIBC - Cholesterol     0.8 0.003     
TIBC - Triglycerides         0.651 0.022
UIBC - Cholesterol     0.673 0.023     
UIBC - Triglycerides       0.58 0.048   
Hepcidin - SOD     -0.6 0.05 0.615 0.033   
Hepcidin - CAT -0.316 0.032         
Hepcidin - GPx         -0.636 0.026
Abbreviations: CAT: catalase, GPx: glutathione peroxidase, LPOx: lipid peroxidation, SOD: superoxide 
dismutase, TIBC: total iron-binding capacity, UIBC: unsaturated iron-binding capacity, %S: iron percentage 
saturation, WLRP: Women with Low-Risk pregnancy, WHRP: Women with High-Risk Pregnancy.  
Cont... Table 4. Correlation of biomarkers of iron profile and hepcidin with blood chemistry and oxidative 
stress
Discussion
The results of this study showed a similar increase in 
cholesterol and triglycerides in both groups of volunteers 
from the 2nd to the 3rd trimester of pregnancy. Similar 
results to previous published information.11,12,13 In this 
survey, 34.1% of pregnant women in the WHRP group 
were hypertensive and 51.2% were dyslipidemic.
On the other hand, SOD and GPx levels increased 
significantly from the 2nd to the 3rd trimester of 
pregnancy, in both groups, probably to offset the effect 
of lipid peroxides and other free radicals produced by 
abnormal lipid metabolism and inflammation processes 
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present when metabolic disturbances occur during 
pregnancy.12
Regarding the iron profile, it was found that the 
volunteers of both groups presented normal serum iron 
levels (60 to 170 µg/dL). However, the TIBC in the 
3rd trimester of the WLRP group and in the 2nd and 
3rd trimester of the WHRP group were higher than the 
reference values  (240 to 450 µg/dL),14 which would 
indicate the absence of iron deficiency in both groups, 
and that by increasing the serum iron concentration, 
it also increases the binding capacity of transferrin 
and binding sites. This hypothesis is reaffirmed by 
the positive relationship between serum iron and iron 
saturation values,15 as well as a negative relationship 
between UIBS and iron saturation.
Overall, the positive relationship between iron 
levels and TIBC in the 3rd trimester in the WHRP 
group would indicate a probable iron overload when 
the binding capacity with transferrin saturates, leading 
to non-transferrin-bound iron being internalized in 
tissues,16 where the ROS would increase, unbalancing 
the antioxidant systems, reflected in the negative 
relationship between serum iron with CAT and the 
positive relationship with GPx, as well as the formerly 
described increase in GPx, affecting insulin secretion 
and lipid oxidation, resulting in increased sensitivity to 
insulin and predisposition to GDM.17 
It is worth noting that excess free iron can accept 
and donate electrons not only to catalyze the Fenton and 
Haber-Weiss reaction, but also to propagate free radical 
chain reactions, acting as an oxidative substance with 
a role in endothelial destruction, and thus participating 
in the pathogenesis of preeclampsia or GDM,18 
pathologies present in the WHRP group. Usually, 
efficient iron mobilization of reserves is reflected by 
lower concentrations of ferritin in the 3rd trimester of 
pregnancy,19 contrary to our results in both groups, in 
which we found an increase, although not significant.
When analyzing hepcidin levels, a significant 
increase from the 2nd to the 3rd trimester, in both groups, 
was found, data consistent with those reported early in 
high-risk pregnancies associated with inflammatory 
conditions (GDM or preeclampsia), in which hepcidin 
rises compared with healthy pregnancies, suggesting 
a probable iron accumulation as a result of the sulfate 
ferrous prescription, since when finding a state of poor 
iron in pregnancy low levels of hepcidin have been 
found,20 being the lowest during the 3rd trimester 
compared with the 1st and 2nd trimester, allowing 
maximum iron transfer to the fetus.21 
The previous result points to the relevance of 
measuring hepcidin during pregnancy. For example, 
finding low levels of it could identify pregnant women 
who need iron supplementation before other iron status 
parameters, like hemoglobin change.19 Conversely, in 
this cohort, the two patients with the highest values of 
hepcidin developed preeclampsia.19
In support of the notion of the importance of 
hepcidin is the finding of a negative relationship between 
this hormone and SOD in the WLRP group, reflecting 
the increase in hepcidin expression due to the increment 
in systemic iron, which in turn helps to reduce iron-
mediated oxidative stress by increasing SOD activity,14 
causing an increase of LPOx levels, without implying 
metabolic damage when negatively related to glucose. 
In the WHRP group, antioxidant activity was affected 
by iron, a situation reflected by the positive relationship 
of hepcidin with SOD, causing greater metabolic damage 
in the 3rd trimester of pregnancy when presenting an 
increase in the levels of GPx described before, a positive 
relationship between cholesterol with GPx and LPOx, 
as well as glucose levels with triglycerides, coinciding 
in part with a previously reported relationship between 
triglycerides and SOD in patients with preeclampsia 
where it would increase the risk of vascular disorders 
that trigger endothelial dysfunction, atherosclerosis and 
thrombosis,12 so that oxidative stress and insufficiency 
in antioxidant defense systems could be factors that 
lead to an increase in lipid peroxidation in metabolic 
diseases such as preeclampsia and GDM,22 in addition 
to previously described elevated serum concentrations 
of ferritin and hepcidin, which lead to insulin resistance 
due to sensitization of peripheral glucose receptors.23
A previous study in Mexico evaluated the intake of 60 
mg of iron, finding that it caused elevations in hemoglobin, 
serum ferritin, iron, and LPOx, demonstrating that 
excessive iron intake during pregnancy could be one of 
the causes of cellular damage.24 Iron overload has also 
been evaluated in mouse studies, demonstrating that 
it can generate a pathology similar to that observed in 
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T2DM, leading to hyperglycemia, hyperinsulinemia, 
lipid synthesis induction and insulin resistance, as well 
as increased production of proinflammatory cytokines, 
such as interleukin (IL)-6, which induces the hepcidin 
gene transcription.25
It can be concluded from this study that in both 
circumstances, High-Risk and Low-Risk pregnancies, 
an increase in systemic iron levels can occur due to 
an overload induced by iron supplements without a 
confirmed diagnosis of anemia. The possibility exists 
that in women with Low-Risk, despite the fact that 
the antioxidant enzyme systems are responding to the 
presence of ROS, they are not totally effective since 
there is a significant increase in LPOx of the 2nd to the 
3rd trimester of pregnancy. 
A limitation of this study is the small number of 
patients. Notwithstanding, a final important message is 
that hepcidin measurement in pregnancy is important 
as it is the regulating hormone of iron homeostasis, and 
may be a useful biomarker to determine the availability 
of iron in pregnancy and its association with antioxidant 
systems could establish whether the increase in serum 
iron is one of the factors that lead to the development 
of metabolic disorders such as preeclampsia, GDM and 
dyslipidemia. 
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